Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Carmat    ALCAR   FR0010907956

CARMAT

(ALCAR)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
03/12/2019 03/13/2019 03/14/2019 03/15/2019 03/18/2019 Date
21.85(c) 21.95(c) 22.2(c) 22.5(c) 22.35 Last
8 627 2 788 1 420 1 870 2 096 Volume
+0.23% +0.46% +1.14% +1.35% -0.67% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -43,3 M
Net income 2019 -39,3 M
Debt 2019 20,7 M
Yield 2019 -
Sales 2020 9,15 M
EBIT 2020 -51,9 M
Net income 2020 -42,7 M
Debt 2020 29,2 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 0
EV / Sales2020 26,1x
Capitalization 210 M
More Financials
Company
Carmat specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all... 
More about the company
Surperformance© ratings of Carmat
Trading Rating : Investor Rating :
More Ratings
Latest news on CARMAT
02/13CARMAT : Reports Its 2018 Annual Results and Confirms Its 2019 Development Prosp..
BU
01/21CARMAT : 2019 Financial Calendar
BU
01/16CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
AQ
01/15CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
BU
2018CARMAT : Juncker Plan - The EIB supports CARMAT with EUR 30m
AQ
2018CARMAT : The European Investment Bank supports CARMAT with €30m for the marketin..
PU
2018CARMAT : The European Investment Bank Supports CARMAT with €30 Million for the M..
BU
2018CARMAT : Announces the Appointment of Pascale d'arbonneau as Chief Financial Off..
BU
2018CARMAT : Announces the Appointment of Jean-Pierre Garnier as Chairman of the Boa..
BU
2018CARMAT : reports its 2018 half-year results and provides an update on its develo..
BU
More news
Analyst Recommendations on CARMAT
More recommendations
Sector news : Medical Devices & Implants
03/14ABBOTT LABORATORIES : Vascular Gets FDA Approval for New Indication for Valve Re..
DJ
03/14GLOBAL MARKETS LIVE : Boeing, Facebook, Volkswagen, Tesla…
03/14STRYKER : Buys OrthoSpace Ltd. for Initial $110 Million
DJ
03/13LEONARDO DEL VECCHIO : Del Vecchio wants to split powers with aide as EssilorLux..
RE
03/13ESSILORLUXOTTICA : Essilor says top shareholder's proposals not in merger agreem..
RE
More sector news : Medical Devices & Implants
Chart CARMAT
Duration : Period :
Carmat Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARMAT
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 30,2 €
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Stéphane Piat Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
Pascale d’Arbonneau Chief Financial & Administrative Officer
Marc Grimmé Director-Research & Development
Piet Jansen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CARMAT-4.26%238
STRYKER CORPORATION23.79%72 312
SMITH & NEPHEW1.09%17 208
WRIGHT MEDICAL GROUP NV18.77%4 069
GLAUKOS CORP28.61%2 612
DOUBLE MEDICAL TECHNOLOGY INC--.--%2 025